



Open Access Full Text Article



Review Paper

## A Review on Diabetic Peripheral Neuropathy

Jasaswi Ray\*, Chinmaya Keshari Sahoo, Rajashree Mohanty, Rakesh Sahoo, Rajashree Dalai

Department of Pharmacy, College of Pharmaceutical Sciences, Bidyaniketan, Puri-Konark marine drive Road, Puri, Odisha-752002

### Article Info:



#### Article History:

Received 10 Feb 2021  
Review Completed 19 March 2021  
Accepted 28 March 2021  
Available online 15 April 2021

#### Cite this article as:

Ray J, Sahoo CK, Mohanty R, Sahoo R, Dalai R, A Review on Diabetic Peripheral Neuropathy, Journal of Drug Delivery and Therapeutics. 2021; 11(2-s):121-125  
DOI: <http://dx.doi.org/10.22270/jddtv1i2-s.4642>

#### \*Address for Correspondence:

Jasaswi Ray, Department of Pharmacy, College of Pharmaceutical Sciences, Bidyaniketan, Puri-Konark marine drive Road, Puri, Odisha-752002

### Abstract

Diabetic peripheral neuropathy (DPN) is a common complication of both type 1 and type 2 diabetes affecting over 90% of the diabetic patients. Due to the toxic effects of hyperglycemia there is development of this complication. It is typically characterized by significant deficits in tactile sensitivity, vibration sense, lower-limb proprioception, and kinesthesia. Painful DPN has been shown to be associated with significant reductions in overall quality of life, increased levels of anxiety and depression, sleep impairment, and greater gait variability. Hence DPN is often inadequately treated, and the role of improving glycaemic control in diabetes. Major international clinical guidelines for the management of DPN recommend several symptomatic treatments. First-line therapies include tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, and anti-consultants that act on calcium channels. Other therapies include opioids and topical agents such as capsaicin and lidocaine. The objectives of this paper are to review current guidelines for the pharmacological management of DPN.

**Keywords:** DPN, hyperglycemia, depression, lidocaine

## INTRODUCTION

Diabetic neuropathy comprises the disorder of peripheral nerve in people suffering with diabetes mellitus. Diabetes has become one of the largest global health care problems of the 21st century. It was estimated that around 415 million people worldwide suffered from diabetes in the year 2015, and these value are expected to increase to 642 million people by the year 2040<sup>1</sup>. Almost 50% of the people suffering through diabetes are expected to develop Diabetic peripheral neuropathy<sup>2</sup>. Diabetic peripheral neuropathy<sup>3</sup> is defined as "presence of symptoms and/a sign of peripheral nerve dysfunction in people with diabetes after exclusion of other causes". Diabetic peripheral neuropathy has devastating effect in the day to day life of the patient. Patient with Diabetic neuropathy repay firstly pain in the lower limbs of their body. This pain may be of different types like sensation of burning, sensation of electric shock, pricking of needle etc. In some cases patient also suffer through loss of sensation. DPN significantly affects the quality of life of the patient and management of wealth (due to disease). Once diagnosed DPN leads to new challenges in the patient management.

## EPIDEMIOLOGY

The epidemiology and natural history of patients are difficult to describe because of various clinical diagnostic criteria, variable selection of patients i.e. (patients with or without pain) and wide ranging physiological techniques. The EURODIAB complications study identified a prevalence of 28% for DPN at baseline with glycemic control and duration

of diabetes being major determinants similar data was observed in the Diabetes Control and Complications Trial (DCCT)<sup>4</sup>. In a study of 4400 patients, the prevalence of DPN was found to be about 75% of newly diagnosed<sup>5</sup> diabetes increasing to be 45% after 25 years of diabetes.

## RISK FACTOR FOR DPN

The risk factor for DPN was determined by EURODIAB on 1100 people with type 1 diabetes followed over a period of 7.5 years<sup>6</sup>. These risk factor was similar to macrovascular disease like hypertension, smoking, increased lipid levels, duration of diabetes and body mass index<sup>7</sup>. It was seen that neuropathic pain is also associated with other diseases like peripheral arterial disease (non-diabetic subject). So this is an important factor in diagnosis and treatment of neuropathic pain<sup>8</sup>.

## CLINICAL FEATURES/ SYMPTOMS

The signs of diabetic neuropathy are variable. The neuropathic pain includes deep, aching pain with superimposed burning and stabbing pain. From a survey it was found that between 25% and 39% of patients may lack adequate treatment for their pain leading negative impact on quality of life<sup>9</sup>. The pain has been reported to in with general activity, mood, mobility, work, social relations, sleep, leisure activities, walking ability and enjoyment of life<sup>10</sup>.

## ETIOLOGY

Although exact cause of diabetic neuropathy is not known but it is thought to be caused due to nerve dysfunction and

cell break and that results from oxidative stress and inflammation<sup>11</sup>. Various health condition like hyperglycemia, dyslipidemia and insulin resistance all contribute towards dysfunction of various metabolic pathways like polyol pathway that sum up to cause the excess formation of mitochondrial and cytosolic reactive oxygen species<sup>12</sup>. These reactive oxygen species cause the injury to the axon of the nerve of the PNS hence leading to DPN. Multiple neurotransmitter also affect the pain pathway.

## PATHOPHYSIOLOGY

The development of DPN is multifactorial. The harmful metabolic effects of chronic hyperglycemia and effect of ischemia to the peripheral nerves are supposed to be the two mechanisms leading to dysfunction and damage. The pathophysiological effects of hyperglycemia are wide variety and include: activation of polyol pathway, generation of reactive oxygen species (ROS) (Oxidative stress), and reactive nitrogen species (Nitrosative stress) and accumulation of advanced glycation end products (AGE)<sup>13</sup>. Excess glucose in the body is metabolized by polyol or sorbitol pathway. In this pathway glucose is reduced to sorbitol by the enzyme aldose reductase, (rate limiting step) before being oxidized by sorbitol dehydrogenase to fructose which is a potent glycation agent. The intracellular accumulation of sorbitol leads to reduction in nerve myoinositol and taurine and disruption of Na<sup>+</sup> / K<sup>+</sup>-ATPase membrane activity leading to accumulation of sodium in nerve, dysfunction of axon and structural damage the nerves.<sup>6,14</sup> The basement membrane of endothelial cells becomes glycosylated due to glycation of free amino group of protein, lipids and nucleic acid with alteration in their molecular structure and function.<sup>15</sup> This leads to impaired vasodilation. Additionally the accumulated AGEs bind to receptor of AGE on macrophages with production of inflammatory cytokines (IL-1), tumor necrosis factor, growth factor and adhesion molecules(VCAM-1)<sup>16</sup>. Another novel pathway that's leads to complications of diabetes is activation of nuclear enzyme poly (ADP ribose) polymerase (PARP). Increased oxidative stress results in DNA damage and PARP 1 activation leading to cellular energy failure which is thought to be important in the pathogenesis of DPN.<sup>17</sup>

## TREATMENT OF DPN

The DPN represent a great therapeutic challenge in pharmacological aspects. As the exact pathophysiology of the disease is unknown. Hence it can't be cured completely but it can be prevented as the pain can be reduced by the following three main principles: glycemic control, foot care and pain management<sup>18</sup>. The glycemic control and foot care efforts are largely preventive. Lifestyle intervention including weight loss and physical activity may also be helpful in treatment of DPN. Pharmacological treatment is indicated. The American diabetes association recommends medication for the relief of pain Andrew symptoms related to diabetic peripheral neuropathy which is known to improve patient quality of life. Drug like Duloxetine and Pregabalin are approved by the US Food and Drug Administration (FDA) for the treatment of diabetic peripheral neuropathy<sup>19,20</sup>. Tricyclic antidepressants drugs are also used for treatment of DPN (to reduce pain) but it is not currently approved by FDA due to the risk of major side effects<sup>21,22</sup>. Opioids can also be used to lower neuropathic pain but these are not recommended as they are habit forming drug. Hence they should not be used for first and second line therapy for neuropathic pain.

## TREATMENT STRATEGIES

Patients diagnosed with DPN experience painful symptoms as we studied above, tight glucose control, moderate exercise and balanced diet may not be sufficient to reverse disease progression, therefore restoration of function, patient education and pharmacological therapy becoming necessary for treatment. The value of tight glucose control in DPN patients was demonstrated in both the United Kingdom Prospective Diabetes Study and the Diabetes Control and Complications Trial (DCCT).<sup>23,24</sup> There are several guidelines recommended the use of pharmacological treatments both approved and off-label to reduce pain and to improve quality of life in DPN patients. These treatments include anti-depressant, anticonvulsant, analgesic, and topical medications. A wide variety of drugs used alone or in combination has been also shown significantly reduce neuropathic pain.

Three different agents have regulated approval for the treatment of DPN i.e. Pregabalin, Duloxetine, and Tapentadol<sup>25,26</sup>.

### Anticonvulsant

Pregabalin was the first anticonvulsant to receive approval from the Food and Drug Administration (FDA) for the treatment of DPN<sup>27,28</sup> and neuropathic pain after spinal cord injury<sup>29</sup>. Pregabalin is also proposed to be the result of improved trafficking of  $\alpha$ 2- $\delta$  subunits with a consequent diminishes expression of function Ca 2+ channels<sup>30</sup>. In addition to analgesic effects, Pregabalin present anxiolytic ability<sup>31,32</sup> and it has a beneficial effects on sleep and quality of life<sup>31</sup>. Therefore contributing to improve the general condition of patients. Side effects include dizziness, somnolence, peripheral oedema, headache and weight gain<sup>33</sup>. Besides Pregabalin, Gabapentin is the only other anticonvulsant drug that is used for treatment of DPN. Some clinical trials have suggested that Gabapentin and Pregabalin present better analgesic efficiency than tricyclic antidepressants or Opioids. Other important aspects of this drug include its tolerability and lack of serious toxicity.

### Antidepressants

Anti-depressant represents the first-line of drug in DPN Management. Duloxetine, a serotonin and norepinephrine reuptake inhibitor, is rated level A for efficacy and is approved in the United States for the treatment of this condition<sup>34</sup>. The analgesic efficacy of Duloxetine in the treatment of DPN is maintained over a 6 month period<sup>35</sup>. Hence it is a preferred drug for the treatment of DPN. Side effects are nausea, somnolence and dizziness as side effects. Other TCA like Amitriptyline and nortriptyline are found to effective in treatment of DPN. Most common side effects are postural hypotension, arrhythmias, congestive impairment, constipation and urinary retention. These side effects are more frequently observed after amitriptyline than nortriptyline treatment.<sup>36</sup>

### Opioids

Opioids are used as second or third line treatment of DPN<sup>33,37</sup>. Opioids like morphine and tramadol can be used to lower DPN but they have some side effects like nausea headache and somnolence<sup>38</sup>. Tapentadol has been shown to be effective in management of different types of chronic pain, low back pain and DPN with a tolerable safety profile<sup>39,40</sup>. Trials have reported reduction of at least 30% in pain intensity in about 50% of the patients that reserved Tapentadol.<sup>41</sup>

### Capsaicin Topical Cream

Use of topical products may lead to less possibility of adverse effects. In addition the possibilities of drug interaction are markedly reduced by the use of topical local treatments which represent good options for patients with multiple medical problems<sup>42</sup>. The capsaicin cream has been shown to be effective in the treatment of neuropathic conditions<sup>43</sup> and is approved for topical relief of pain<sup>42</sup>. There are some adverse effects linked with capsaicin cream which include itching, stinging, erythema, transient burning sensation and initial pain at the site of application that diminishes with repeated use.<sup>44,45</sup>

### Lidocaine Patch

Lidocaine patches acts as peripheral analgesic with minimal systemic absorption and currently used with other analgesic drugs<sup>44,46</sup>. Lidocaine acts as sodium channel blockers thereby counteracts the hyper excitability of peripheral nociceptors that contributes to neuropathic pain<sup>34,44,47</sup>. Adverse effects are local irritation, contact dermatitis and itching.

### Alpha Lipoic Acid

Alpha lipoic acid(ALA) acts as an antioxidant thereby it reduces oxidative stress, which is an important factors in pathophysiology of Diabetic neuropathy<sup>34</sup>. Its antioxidant and anti-inflammatory actions may contribute to an all-round improvement of diabetic neuropathy symptoms<sup>48</sup>. ALA has the least side effects among all the various other drugs used for treatment of DPN. The common side effects of ALA is nausea and vomiting.<sup>44</sup>

## POPULATION STUDY

The most common and debilitating microvascular complication of diabetes is diabetic peripheral neuropathy (DPN), affecting 50-90% of people with diabetes<sup>49</sup>. The major manifestations of DPN are painful (pDPN) and painless diabetic peripheral neuropathy. The explosion of diabetes, especially in the South East Asian (SEA) region will result in an increasing prevalence of both painful and painless diabetic peripheral neuropathy. In the United States (US) and Europe, pDPN is estimated to occur in up to one-third of all patients with diabetes<sup>50,51,52,53,54</sup>. Although diabetes is an increasing problem in Asia<sup>55,56,57</sup> studies estimating the prevalence of pDPN are scarce. In a nationwide, observational study of approximately 4000 patients with type2 diabetes in Korea, the estimated pDPN prevalence was 14.4%, or 43.1% of patients with DPN<sup>58</sup>. In Japan, 22.1% of 298 diabetic out patients were found to have pDPN<sup>59</sup>.

### Bangladesh

In a study from 2006, the prevalence of DPN was 19.7% in randomly selected patients with Type 2 Diabetes Mellitus (T2DM) aged  $50.8 \pm 10.6$  years and increased with age and duration of diabetes the prevalence increases.<sup>60</sup> In a study from 2012 in the outpatient department the prevalence of DPN was 35% with was a cross sectional study of 140 patients<sup>49</sup>. In another study of 400 patients, neuropathy was diagnosed from the medical records and a prevalence of 16.8% was established.<sup>61</sup>

### India

A cross sectional study in 2013 was undertaken in North India in 586 participants of whom 18.4% were newly diagnosed (< 6 months) and 81.6% had known diabetes with a mean age of  $57.1 \pm 9.7$  years and mean duration of diabetes of  $10.8 \pm 7.5$  years with the help of Semmes-Weinstein

monofilament (SWM) and vibration perception threshold (VPT).<sup>49</sup> Similarly a study from South India with 1000 diabetic patients underwent biothesiometry and assessment of VPT, the prevalence was found to be 19.1%.<sup>62</sup> A retrospective study from Goa of 3261 patients with T2DM established a prevalence of 16.3%.<sup>63</sup> In another study of 1500 patients with young onset diabetes aged  $34.68 \pm 4.23$  years, the prevalence of advanced neuropathy, the prevalence was found to be 13.1%.<sup>64</sup> In a retrospective study of 249 T2DM patients in a tertiary setting, a surprisingly low prevalence of 14.4% was established, but the method of diagnosing neuropathy was not disclosed.<sup>65</sup> A study of 1319 T2DM patients from 4 centers across India, SWM insensitivity the prevalence was found to be 15%.<sup>66</sup>

### Sri Lanka

In a study of 528 diabetic patients of which 191 were newly diagnosed patients, used Diabetic Neuropathy symptom (DNS) score to determine DPN relevance of 48.1%.<sup>49</sup> Test on Toronto clinical scoring system (TCSS) the prevalence with known Diabetes was found to be 24%.<sup>67</sup> A most recent study with taking 8401 people was done in a Diabetic centre in Jaffna established as DPN prevalence of 34.1%.<sup>68</sup> In a further study of 1007 young Diabetic patients aged  $36.6 \pm 11.17$  years with diabetes duration of  $4.8 \pm 4.2$  years, using neurological symptoms the DPN relevance was found to be 30.7%.<sup>49</sup>

### Thailand

In a retrospective study of 1110 (T1DM-6%, T2DM- 94%) diabetic patients from 37 primary health care clinics Indonesia the prevalence of DPN was found to be 34%.<sup>69</sup> While in an another study with 899 Thai T2DM patients underwent assessment with the SWM (Semmes-Weinstein monofilament) on seven areas of the foot and 15.9% were diagnosed with advanced neuropathy and deemed at high risk of foot ulceration<sup>70</sup>. Similarly cross-sectional study of 438 diabetic patients from a tertiary care diabetes clinic, insensitivity to the SWM was found in 19.2%.<sup>71</sup>

### Indonesia

A cross sectional study of 1785 people in Indonesia was done between 2008-2009 and the prevalence of DPN was found to be 67.1%.<sup>72</sup> In similar studies from Surabaya assessed the medical records of 302 T2DM patients and found the prevalence of DPN to be 58.6%.<sup>73</sup>

## CONCLUSION

DPN remains a common and disabling complication of diabetes. The treatment should be focused on identification of risk factors, implementation of diabetic foot care program, symptom relief to improve quality of life and patient education is the key. Approaches like gene therapy and targeted delivery of antioxidant therapy may in the future would offer the best potential to reverse this common and disabling complication of diabetes. Approx 50% adult with diabetes will be affected by peripheral neuropathy in their lifetime, more diligent screening and management would be the key to reduce complications and health care burden associated with the disease.

## REFERENCES

1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. *Diabetes Res Clin Pract.* 2014; 103(2):137- 149. doi:10.1016/j.diabres.2013.11.002
2. Zhou H, Zhang W. Gene expression profiling reveals candidate biomarkers and probable molecular mechanism in Diabetic peripheral neuropathy. *Diabetes, Metabolic Syndrome and*

Obesity: Targets and Thearay 2019; 12:1213-1223 [Dovepress: 117.240.133.202]

3. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med.* 2002; 346(6):393-403.10.1056/NEJMoa012512 [PubMed: 11832527]
4. American Diabetes Association. American Academy of Neurology: Report and recommendations of the San Antonio conference on diabetic neuropathy. *Diabetes Care.* 1988; 11:592-597.
5. Toeller M, Buyken AE, Heitkamp G, et al. Prevalence of chronic complications, metabolic control and nutritional intake in type 1 diabetes: comparison between different European regions. *EURODIAB Complications Study group. HormMetab Res.* 1999; 31:680-685.
6. Shakher J, Stevens MJ. Updates on the management of diabetic polyneuropathies. *Diabetes, Metabolic Syndrome and Obesity: Targets and Thearay* 2011; 4:289-305 [Dovepress: 117.240.133.202]
7. Ziegler D, Gries FA, Spuler M, Lessmann F. The epidemiology of diabetic neuropathy. *Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. J Diabetes Comp.* 1992; 6:49-57.
8. Tesfaye S, Chaturvedi N, Eaton SE, et al; EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. *N Engl J Med.* 2005; 352:341-350.
9. Ziegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come? *Diabetes Care.* 2008; 31Suppl 2:S255-S261.
10. Armstrong DG, Chappell AS, Le TK, Kajdasz DK, Backonja M, D'Souza DN, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evaluation of functional outcomes. *Pain Med.* 2007; 8:410-418.
11. Feldman EL, Nave KA, Jensen TS, Bennett DLH. New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. *Neuron.* 2017; 93(6):1296-1313.10.1016/j.neuron.2017.02.005 [PubMed: 28334605]
12. Sajic M. Mitochondrial dynamics in peripheral neuropathies. *Antioxid Redox Signal.* 2014; 21(4):601-620.10.1089/ars.2013.5822 [PubMed: 24386984]
13. Chokroverty S, Reyes MG, Rubino FA, et al. The syndrome of diabetic amyotrophy. *Ann Neurol.* 1977; 2:131.
14. Shakher J, Stevens MJ. Updates on the management of diabetic polyneuropathies. *Diabetes, Metabolic Syndrome and Obesity: Targets and Thearay* 2011; 4:289-305 [Dovepress: 117.240.133.202]
15. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature.* 2001; 414:813-820.
16. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end products: a review. *Diabetologia.* 2001; 44:129-146.
17. Vinik AI, Erbas T, Park TS, Stansberry KB, Scanelli JA, Pittenger GL. Dermal neurovascular dysfunction in type 2 diabetes. *Diabetes Care.* 2001; 24:1468-1475.
18. Selvin E, Hicks CW. Epidemiology of Peripheral neuropathy and lower Extremity Disease in Diabetes. *Curr Down Rep.* 19(10):86. DOI: 10.1007/s11892-019-1212-8 [Author manuscript]
19. Onakpoya IJ, Thomas ET, Lee JJ, Goldacre B, Heneghan CJ. Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials. *BMJ Open.* 2019; 9(1):e02360010.1136/bmjopen-2018-023600
20. Ormseth MJ, Scholz BA, Boomershine CS. Duloxetine in the management of diabetic peripheral neuropathic pain. Patient Prefer Adherence. 2011; 5:343-356.10.2147/PPA.S16358 [PubMed: 21845034]
21. Kvinesdal B, Molin J, Froland A, Gram LF. Imipramine treatment of painful diabetic neuropathy. *JAMA.* 1984; 251(13):1727-1730 [PubMed: 6366276]
22. Max MB, Culnane M, Schafer SC, Gracely RH, Walther DJ, Smoller B, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. *Neurology.* 1987; 37(4):589-596.10.1212/wnl.37.4.589 [PubMed: 2436092]
23. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ.* 2000; 321:405-412. [PMC free article] [PubMed] [Google Scholar]
24. Epidemiology of Diabetes Interventions and Complications (EDIC) Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. *Diabetes Care.* 1999; 22:99-111. [PMC free article] [PubMed] [Google Scholar]
25. Freeman R. New and developing drugs for the treatment of neuropathic pain in diabetes. *Curr Diab Rep.* 2013; 13:500-508 [PMID: 23771401 DOI: 10.1007/s11892-013-0396-6]
26. Peltier A, Goutman SA, Callaghan BC. Painful diabetic neuropathy. *BMJ.* 2014; 348:g1799 [PMID: 24803311 DOI: 10.1136/bmj.g1799]
27. Verma V, Singh N, Singh Jaggi A. Pregabalin in neuropathic pain: evidences and possible mechanisms. *Curr Neuropharmacol.* 2014; 12:44-56 [PMID: 24533015 DOI: 10.2174/1570159X1201140117162802]
28. Blommel ML, Blommel AL. Pregabalin: an antiepileptic agent useful for neuropathic pain. *Am J Health Syst Pharm.* 2007; 64:1475-1482 [PMID: 17617497 DOI: 10.2146/ajhp060371]
29. Guy S, Mehta S, Leff L, Teasell R, Loh E. Anticonvulsant medication use for the management of pain following spinal cord injury: systematic review and effectiveness analysis. *Spinal Cord.* 2014; 52:89-96 [PMID: 24296804 DOI: 10.1038/sc.2013.146]
30. Stahl SM, Porreca F, Taylor CP, Cheung R, Thorpe AJ, Clair A. The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities? *Trends Pharmacol Sci.* 2013; 34:332-339 [PMID: 23642658 DOI: 10.1016/j.tips.2013.04.001]
31. Zilliox L, Russell JW. Treatment of diabetic sensory polyneuropathy. *Curr Treat Options Neurol.* 2011; 13:143-159 [PMID: 21274758 DOI: 10.1007/s11940-011-0113-1]
32. Patel N, Mishra V, Patel P, Dikshit RK. A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy. *J Diabetes Metab Disord.* 2014; 13:62 [PMID: 24926454 DOI: 10.1186/2251-6581-13-62]
33. Tesfaye S, Boulton AJ, Dickenson AH. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. *Diabetes Care.* 2013; 36:2456-2465 [PMID: 23970715 DOI: 10.2337/dc12-1964]
34. Schreiber AK, Nones CFM, Reis RC, Chichorro JG, Cunha JM. Diabetic neuropathic pain: Physiopathology and treatment. *World J Diabetes.* 2015; 6(3):432-444 [DOI: 10.4239/wjd.v6.i3.432]
35. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. *Diabetologia.* 2001; 44:1973-1988 [PMID: 11719828 DOI: 10.1007/s001250100001]
36. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: a Cochrane review. *J NeurolNeurosurg Psychiatry.* 2010; 81:1372-1373 [PMID: 20543189 DOI: 10.1136/jnnp.2008.144964]
37. Page N, Deluca J, Crowell K. Clinical inquiry: what medications are best for diabetic neuropathic pain? *J Fam Pract.* 2012; 61:691-693 [PMID: 23256101]
38. Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P, Donofrio P, Cornblath D, Sachdeo R, Siu CO, Kamin M. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. *Neurology.* 1998; 50:1842-1846 [PMID: 9633738]
39. Afilalo M, Morlion B. Efficacy of tapentadol ER for managing moderate to severe chronic pain. *Pain Physician.* 2013; 16:27-40 [PMID: 23340531]
40. Taylor R, Pergolizzi JV, Raffa RB. Tapentadol extended release for chronic pain patients. *Adv Ther.* 2013; 30:14-27 [PMID: 23328938 DOI: 10.1007/s12325-013-0002-y]
41. Schwartz S, Etropolski M, Shapiro DY, Okamoto A, Lange R, Haeussler J, Rauschkolb C. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. *Curr Med Res Opin.* 2011; 27:151-162 [PMID: 21162697 DOI: 10.1185/03007995.2010.537589]
42. Peltier A, Goutman SA, Callaghan BC. Painful diabetic neuropathy. *BMJ.* 2014; 348:g1799 [PMID: 24803311 DOI: 10.1136/bmj.g1799]
43. Deli G, Bosnyak E, Pusch G, Komoly S, Feher G. Diabetic neuropathies: diagnosis and management. *Neuroendocrinology.* 2013; 98:267-280 [PMID: 24458095 DOI: 10.1159/000358728]

44. Zilliox L, Russell JW. Treatment of diabetic sensory polyneuropathy. *Curr Treat Options Neurol* 2011; 13:143-159 [PMID: 21274758 DOI: 10.1007/s11940-011-0113-1]

45. Groninger H, Schisler RE. Topical capsaicin for neuropathic pain #255. *J Palliat Med* 2012; 15:946-947 [PMID: 22849599 DOI:10.1089/jpm.2012.9571]

46. Wolff RF, Bala MM, Westwood M, Kessels AG, Kleijnen J. 5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. *Swiss Med Wkly* 2010; 140:297-306 [PMID: 20458651]

47. Casale R, Mattia C. Building a diagnostic algorithm on localized neuropathic pain (LNP) and targeted topical treatment: focus on 5% lidocaine-medicated plaster. *TherClin Risk Manag* 2014; 10:259-268 [PMID: 24790451 DOI: 10.2147/TCRM.S58844]

48. Patel N, Mishra V, Patel P, Dikshit RK. A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy. *J Diabetes MetabDisord* 2014; 13:62 [PMID:24926454 DOI: 10.1186/2251-6581-13-62]

49. Almuhannadi H, Ponirakis G, Adnan Khan, Rayaz Ahmed Malik. Diabetic neuropathy and painful diabetic neuropathy: Cinderella complications in South East Asia 2018; [Research gate: 322195432]

50. Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. *Pain Med* 2008; 9:660-674. DOI: 10.1111/j.1526-4637.2007.00347.x. [PubMed] [CrossRef] [Google Scholar]

51. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. *Diabetes Care*. 2006; 29:1518-1522. doi: 10.2337/dc05-2228. [PubMed] [CrossRef]

52. Alleman CJ, Westerhout KY, Hensen M, et al. Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: A review of the literature. *Diabetes Res ClinPract*. 2015; 109:215-225. doi: 10.1016/j.diabres.2015.04.031. [PubMed] [CrossRef] [Google Scholar]

53. Sadosky A, McDermott AM, Brandenburg NA, Strauss M. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. *Pain Pract*. 2008; 8:45-56. doi: 10.1111/j.1533-2500.2007.00164.x. [PubMed] [CrossRef]

54. Gregg EW, Sorlie P, Paulose-Ram R, et al. Prevalence of lower-extremity disease in the US adult population  $\geq$ 40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. *Diabetes Care*. 2004; 27:1591-1597. doi: 10.2337/diacare.27.7.1591. [PubMed] [CrossRef] [Google Scholar]

55. Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. *Lancet*. 2006; 368:1681-1688. doi: 10.1016/S0140-6736(06)69703-1. [PubMed] [CrossRef] [Google Scholar]

56. Ramachandran A, Snehalatha C, Shetty AS, Nanditha A. Trends in prevalence of diabetes in Asian countries. *World J Diabetes*. 2012; 3:110-117. doi: 10.4239/wjd.v3.i6.110. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

57. Nanditha A, Ma RC, Ramachandran A, et al. Diabetes in Asia and the Pacific: implications for the Global Epidemic. *Diabetes Care*. 2016; 39:472-485. doi: 10.2337/dc15-1536. [PubMed] [CrossRef] [Google Scholar]

58. Kim SS, Won JC, Kwon HS, et al. Prevalence and clinical implications of painful diabetic peripheral neuropathy in type 2 diabetes: results from a nationwide hospital-based study of diabetic neuropathy in Korea. *Diabetes Res ClinPract*. 2014; 103:522-529. doi: 10.1016/j.diabres.2013.12.003. [PubMed] [CrossRef] [Google Scholar]

59. Tsuji M, Yasuda T, Kaneto H, et al. Painful diabetic neuropathy in Japanese diabetic patients is common but underrecognized. *Pain Res Treat*. 2013; 2013:318352. [PMC free article] [PubMed] [Google Scholar]

60. Morkrid K, Ali L, Hussain A. Risk factors and prevalence of diabetic peripheral neuropathy: A study of type 2 diabetic outpatients in Bangladesh. *Int J Diabetes DevCtries*. 2010; 30:11-7.

61. Khanam PA, Hoque S, Begum T, Habib SH, Latif ZA. Microvascular complications and their associated risk factors in type 2 diabetes mellitus. *Diabetes MetabSyndr*. 2017

62. Ashok S, Ramu M, Deepa R, Mohan V. Prevalence of neuropathy in type 2 diabetic patients attending a diabetes centre in South India. *J Assoc Physicians India*. 2002; 50:546-50.

63. Ankush, Dias A, Gomes E, Dessai A. Complications in Advanced Diabetics in a Tertiary Care Centre: A Retrospective Registry-Based Study. *J ClinDiagn Res*. 2016; 10:OC15-9.

64. Sosale B, Sosale AR, Mohan AR, Kumar PM, Saboo B, Kandula S. CardiovascularCardiovascular risk factors, micro and macrovascular complications at diagnosis in patients with young onset type 2 diabetes in India:CINDI 2. *Indian J EndocrinolMetab*. 2016; 20:114-8

65. Umamahesh K, Vigneswari A, Surya Thejaswi G, Satyavani K, Viswanathan V. Incidence of cardiovascular diseases and associated risk factors among subjects with type 2 diabetes – an 11-year follow up study. *Indian Heart J*. 2014; 66:5-10.

66. Viswanathan V, Thomas N, Tandon N, Asirvatham A, Rajasekar S, Ramachandran A, et al. Profile of diabetic foot complications and its associated complications--a multicentric study from India. *J Assoc Physicians India*. 2005; 53:933-6.

67. Katulanda P, Ranasinghe P, Jayawardena R, Constantine GR, Sheriff MH, Matthews DR. The prevalence, patterns and predictors of diabetic peripheral neuropathy in a developing country. *DiabetolDiabetolMetabSyndr*. 2012; 4:21.

68. Sujanitha V, Sivansuthan S, Selvakaran P, Parameswaran P. Overweight, obesity and chronic complications of diabetes mellitus in patients attending Diabetic Centre, Teaching Hospital,Jaffna, Sri Lanka. *Ceylon Med J*. 2015; 60:94-6

69. Nitityanant W, Chetthakul T, Sang AkP, Therakiatkumjorn C, Kunsuikmengrai K, Yeo JP. A survey study on diabetes management and complication status in primary care setting in Thailand. *J Med Assoc Thai*. 2007; 90:65-71.

70. Sattaputh C, Potisat S, Jongsareejit A, Krairittichai U, Pooreesathian K. Prevalence of factors predisposing to foot complication and their relation to other risks. *J Med Assoc Thai*. 2012; 95:1013-20.

71. Kosachunhanun N, Tongprasert S, Rerkasem K. Diabetic foot problems in tertiary care diabetic clinic in Thailand. *Int J Low Extrem Wounds*. 2012; 11:124-7.

72. Soewondo P, Soegondo S, Suastika K, Pranoto A, Soeatumadiji D, Tjokroprawiro A. The DiabCare Asia 2008 study - outcomes on control and complications of type 2 diabetic patients in Indonesia. *MedMed J Indones*. 2010; 9:235-44.

73. Soewondo P, Ferrario A, Tahapary DL. Challenges in diabetes management in Indonesia: a literature review. *Globalization and health*. 2013; 9:63.